NIH grants license to KannaLife to study CBD & CTE • 2010 - NIH granted KannaLife exclusivity
to develop a treatment for Hepatic Encephalopathy, a disease of the liver and brain that stems from cirrhosis. • 2014 - NIH granted the company an additional license on their previous patent to study CTE. • KannaLife is the only company with licenses on the US-government held patent on cannabinoids.
Made with FlippingBook - Online catalogs